A new clinical study sponsored by Jetema Co., Ltd. is set to evaluate the performance of two injectable treatments—JTM104 and Juvederm® ULTRA PLUS XC—in addressing moderate to severe nasolabial folds. This announcement is relevant for clinical, quality, and regulatory professionals monitoring advancements in aesthetic medicine.
What changed?
Jetema Co., Ltd., the sponsor of this research, has announced a planned clinical trial to assess its proprietary biological JTM104 against Juvederm® ULTRA PLUS XC. While the study has not yet commenced recruitment, it marks a significant step in exploring alternatives for wrinkle reduction.
This trial, once completed, could inform medical device stakeholders about the efficacy and safety profiles of two comparably used products in aesthetic dermatology.
What are the clinical trial details?
Scope of the trial
The research focuses on patients exhibiting moderate to severe nasolabial folds. These facial wrinkles commonly run from each side of the nose down to the corners of the mouth.
Interventions under analysis
The two biological treatments under evaluation are:
- JTM104: A product developed by Jetema Co., Ltd., specifically targeting wrinkle improvements.
- Juvederm® ULTRA PLUS XC: A well-established filler widely used for skin rejuvenation and wrinkle correction.
Status of the study
According to ClinicalTrials.gov records, the trial has a “Not yet recruiting” status as of now. Interested parties can monitor updates via the provided ClinicalTrials.gov link.
Who should pay attention?
This study holds particular relevance for:
- Clinical professionals: Those involved in filler injections or dermatology may stay informed on emerging treatment profiles.
- Quality assurance teams: Focused on performance and safety data of aesthetic medical devices.
- Regulatory teams: Tracking trial updates helps in understanding potential regulatory pathways for dermal fillers.
FAQ
- When does the trial begin recruitment?
The specific recruitment start date has not been announced. Check ClinicalTrials.gov for updates. - What are the conditions studied?
The trial addresses moderate to severe nasolabial folds and associated wrinkle treatments. - Is Juvederm® already FDA-approved?
Yes, Juvederm® ULTRA PLUS XC is an FDA-approved filler. This trial aims to provide comparative efficacy and safety data alongside JTM104.
Conclusion
As Jetema Co., Ltd. prepares to initiate this comparative study, the findings could create meaningful insights into the field of dermal fillers for wrinkle treatment. The study’s outcomes may influence future clinical decisions, device development, and regulatory considerations worldwide.
Disclaimer
This article is for informational purposes only. It does not constitute legal, clinical, or regulatory advice. Always refer to official resources for comprehensive guidance.
Full announcement link
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07265791?term=medical+device